港股异动 | 开拓药业-B(9939.HK)涨近4% 与京东健康签署框架协议
格隆汇6月29日丨开拓药业-B(9939.HK)现报16港元,涨3.9%,暂成交2161万港元,最新总市值59亿港元。开拓药业昨日公布,2020年6月20日,公司全资子公司苏州开拓药业股份有限公司与北京京东健康签署框架协议。根据框架协议,双方将就福瑞他恩(KX-826)在京东健康运营的线上药品零售平台yiyaojd.com(“京东大药房”)的销售展开深入合作。公告称,福瑞他恩正在进行中国的II期临床试验和美国的Ib期临床试验。和京东健康基于该框架协议的合作将提高集团在商业零售渠道的能力,从而为双方创造互惠互利。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.